Article
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Molecular carcinogenesis - 1 Dec 2014
Liu Yi-Chang, Hsiao Hui-Hua, Yang Wen-Chi, Liu Ta-Chih, Chang Chao-Sung, Yang Ming-Yu, Lin Pai-Mei, Hsu Jui-Feng, Lee Ching-Ping, Lin Sheng-Fung
Abstract excerpt
The genetic or functional inactivation of the p53 pathway plays an important role with regards to disease progression from the chronic phase (CP) to blast phase (BP) and imatinib treatment response in chronic myeloid leukemia (CML). Two functional single nucleotide polymorphisms (SNPs), p53 R72P and MDM2 SNP309, are associated with alternation of p53 activity, however the association regarding CML susceptibility...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.